SURF Projected Dividend Yield
Surface Oncology Inc ( NASDAQ : SURF )Surface Oncology is an immuno-oncology company focused on using its knowledge of the biological pathways crucial to the immunosuppressive tumor microenvironment (TME) for the development of cancer therapies. NZV930 and SRF617 are antibodies inhibiting cluster of differentiation (CD) 73 and CD39, respectively, and illustrate how Co.'s knowledge of TME biology can be utilized across programs. SRF388 is an antibody targeting interleukin 27, an immunosuppressive cytokine, or protein that is overexpressed in certain cancers, including hepatocellular, lung and renal cell carcinoma. GSK4381562 is an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells. 20 YEAR PERFORMANCE RESULTS |
SURF Dividend History Detail SURF Dividend News SURF Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |